Radiation plus drug cocktail targets tough colorectal cancer
NCT ID NCT07535632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding targeted radiation (SBRT) and an immunotherapy drug (sintilimab) to standard chemotherapy (TAS-102) and bevacizumab can help people with recurrent metastatic colorectal cancer live longer without their cancer growing. The study will enroll 58 adults who have already tried at least two prior treatments. Participants are randomly assigned to receive either the new combination or standard third-line therapy. The main goal is to see if the new approach delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiation therapy (SBRT), sintilimab, bevacizumab, and trifluridine/tipiracil (TAS-102)
What this could lead to
If successful, this combination could offer a new third-line treatment option that slows cancer growth and improves survival for patients with advanced colorectal cancer.
What could go wrong
This is a small, early-phase trial (58 people) with no results yet. The combination may cause significant side effects or fail to improve outcomes over standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••